Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

NCT05366829 is registered in ClinicalTrials.gov with Rutgers, The State University of New Jersey as lead sponsor.

NCT NCT05366829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05366829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
Lead sponsor
Rutgers, The State University of New Jersey
Phase
Phase 2
Overall status
Recruiting
Start date
July 25, 2022
Completion date
June 1, 2027
Enrollment
35 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular, liver cell carcinoma